Portal de Periódicos da CAPES

Treatment of Pituitary Dwarfism with Authentic Recombinant Human Growth Hormone (SM-9500)

1987; Japan Endocrine Society; Volume: 34; Issue: 2 Linguagem: Inglês

10.1507/endocrj1954.34.291

2185-6370

Kazue Takano, KAZUO SHIZUME, Itsuro Hibi, Akimasa Okuno, K Hanyu, Seizo Suwa, Hironori Nakajima, Takuma Kondo, Kiyohiko Kato, Noritaka Iwatani, T Momoi, Kazuo Chihara, ETSUHISA SHIRAKAWA, Hitoshi Kohno,

Connective tissue disorders research

Twenty-one patients with pituitary dwarfism were treated with methioninefree hGH (r-hGH) for6months with a dosage of 0.5IU/kg/week. The height of newly treated patients (N=14), increased from 2.4 to 5.0cm during treatment, which corresponded to from 4.8 to 10.0cm with a mean of 8.1±0.5cm/year. In switched patients (N=7), height increased from 2.2 to 3.8cm during the treatment, which corresponded to 4.4-7.6cm with a mean of 6.1±0.5cm/year, which was similar to that observed in previous treatment with pituitary extracted hGH (p-hGH). Anti-hGH antibody was observed in two patients (9.5%) at the end of6months of treatment with a titer of 10. These data indicate that r-hGH has a growth promoting effect and low antigenicity.